hypotension/obesity

FIELD OF THE INVENTION The present invention is directed to alicyclic imidazoles which interact with the histamine H.sub.3 receptor as agonists, antagonists or inverse agonists; pharmaceutically active compositions containing such compounds; and the use of such compounds in formulations for the

FIELD OF THE INVENTION This invention relates, in part, to newly identified polynucleotides and polypeptides; variants and derivatives of the polynucleotides and polypeptides; processes for making the polynucleotides and the polypeptides, and their variants and derivatives; agonists and antagonists

BACKGROUND AND SUMMARY OF THE INVENTION The present invention relates to the use of morphinan derivatives as well as their bases or salts of physiologically compatible acids as regulators for the nociceptin/orphanin FQ ligand ORL1 receptor system and for the production of a medicament. The

FIELD OF THE INVENTION The present invention relates to phenyl-alkyl-imidazoles having valuable pharmacological properties, especially CNS activities and activity against inflammatory disease. Compounds of this invention are antagonists of the H.sub.3 receptor. BACKGROUND OF THE INVENTION European

FIELD OF THE INVENTION The present invention relates to novel phenyl-alkyl-imidazoles having valuable pharmacological properties, especially CNS activities and activity against inflammatory disease. Compounds of this invention are antagonists of the H.sub.3 receptor. BACKGROUND OF THE

BACKGROUND H.sub.3 receptor sites are known and are of current interest to those skilled in the art--for example, see: West, Jr. et al., "Biexponential Kinetics of (R)-.alpha.-[.sup.3 H]Methylhistamine Binding to the Rat Brain H.sub.3 Histamine Receptor", Journal of Neurochemistry, Vol. 55, No. 5,

BACKGROUND OF THE INVENTION This invention is directed to compounds of formula I described herein, to a pharmaceutical composition comprising such compounds, and to methods of treatment of disorders or conditions that may be treated by antagonizing histamine-3 (H3) receptors using such compounds.

The entire disclosure of parent application 60/541,151 filed Feb. 2, 2004 is fully incorporated herein by reference thereto. BACKGROUND OF THE INVENTION This invention is directed to compounds of formula I described herein, to pharmaceutical composition comprising such compounds, and to methods of

BACKGROUND OF THE INVENTION This invention is directed to compounds of formula I described herein, to a pharmaceutical composition comprising such compounds, to a process of preparation of such compounds, and to methods of treatment of disorders or conditions that may be treated by antagonizing

BACKGROUND OF THE INVENTION This invention is directed to compounds of formula I described herein, to a pharmaceutical composition comprising such compounds, to a process of preparation of such compounds, and to methods of treatment of disorders or conditions that may be treated by antagonizing

FIELD OF THE INVENTION This invention relates to methods for discovering agonists and antagonists of the interaction between UDP-sugars (e.g.,UDP-glucose, UDP-galactose, UDP-glucuronic acid, and UDP-N-acetyl glucosamine) and their cellular receptor, human KIAA0001 receptor. The invention also

The present invention is directed to the tosylate salt of the compound of formula 1, as described herein, to a pharmaceutical composition comprising this salt, and to methods of treatment of disorders or conditions that may be treated by antagonizing histamine-3 (H.sub.3) receptors using the

FIELD OF THE INVENTION The present invention relates to sulfonamide derivatives, to the process for preparing them and to their therapeutic use. BACKGROUND OF THE INVENTION Orexins A and B (or hypocretins 1 and 2) are hypothalamus neuropeptides of 33 and 28 amino acids, respectively, recently

FIELD OF INVENTION This invention relates to newly identified polynucleotides, polypeptides encoded by them and to the use of such polynucleotides and polypeptides, and to their production. More particularly, the polynucleotides and polypeptides of the present invention relate to G-protein coupled

FIELD OF INVENTION This invention relates to newly identified polynucleotides, polypeptides encoded by them and to the use of such polynucleotides and polypeptides, and to their production. More articularly, the polynucleotides and polypeptides of the present invention relate to G-protein coupled